Advertisement
U.S. markets closed

Protalix BioTherapeutics, Inc. (PLX)

NYSE American - NYSE American Delayed Price. Currency in USD
1.2700-0.0600 (-4.51%)
At close: 04:00PM EDT
1.2800 +0.01 (+0.79%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close1.3300
Open1.3200
Bid1.2700 x 1400
Ask1.3100 x 1100
Day's Range1.2693 - 1.3300
52 Week Range1.2100 - 3.5500
Volume695,085
Avg. Volume325,083
Market Cap92.776M
Beta (5Y Monthly)0.91
PE Ratio (TTM)14.11
EPS (TTM)0.0900
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
88% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PLX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Protalix BioTherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/23/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    5 months agoArgus Research
View more
  • Insider Monkey

    Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript

    Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript March 14, 2024 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.03. Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]

  • Zacks Small Cap Research

    PLX: Elfabrio Geographic Expansion

    By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Full Year 2023 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced full year 2023 financial and operational results in a March 14th, 2024 press release and filing of Form 10-K . The reports were followed by a conference call which discussed recent achievements, regulatory updates and financial

  • GuruFocus.com

    Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023

    PLX Sees Regulatory Approvals and Commercial Progress Amidst Financial Growth